- Conditions
- Multiple Myeloma
- Interventions
- Pack Health's digital life coaching (DLC)
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 20,604
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
- Interventions
- Selinexor, Ruxolitinib, Methylprednisolone
- Drug
- Lead sponsor
- Oncotherapeutics
- Industry
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- West Hollywood, California
- Conditions
- Type1 Diabetes Mellitus
- Interventions
- Insulet automated glucose control system
- Device
- Lead sponsor
- Insulet Corporation
- Industry
- Eligibility
- 2 Years to 85 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 3
- States / cities
- Palo Alto, California • Denver, Colorado • New Haven, Connecticut
- Conditions
- HIV Infections
- Interventions
- Not listed
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 13 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- IgA Nephropathy, Focal Segmental Glomerulosclerosis, Alport Syndrome, Diabetic Kidney Disease, Diabetic Nephropathy Type 2, Immunoglobulin A Nephropathy
- Interventions
- Atrasentan
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 14
- States / cities
- Glendale, California • Los Angeles, California • San Dimas, California + 11 more
- Conditions
- Heart Failure With Preserved Ejection Fraction (HFPEF), Heart Failure With Normal Ejection Fraction, Heart Failure, Diastolic
- Interventions
- Exogenous Ketone Drink, Placebo
- Dietary Supplement
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Multiple Sclerosis
- Interventions
- Interferon-beta 1b (Betaseron)
- Drug
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Type 2 Diabetes, Insulin Dependent Diabetes
- Interventions
- Not listed
- Lead sponsor
- Clinical Nutrition Research Center, Illinois Institute of Technology
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Food Allergy, Eosinophilic Esophagitis
- Interventions
- Not listed
- Lead sponsor
- Children's Hospital of Philadelphia
- Other
- Eligibility
- 1 Month to 65 Years
- Enrollment
- 5,300 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2031
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Lymphoma, Myelodysplastic Syndromes
- Interventions
- BPX-501 dose 1, Rimiducid, BPX-501 dose 2, BPX-501 dose 3, BPX-501 dose 4, SCT
- Biological · Drug · Procedure
- Lead sponsor
- Bellicum Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2032
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Buffalo, New York • New York, New York + 4 more
- Conditions
- HIV Infections
- Interventions
- Zidovudine, Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 70
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
- Conditions
- Graves Disease, Hyperthyroidism
- Interventions
- Potassium Iodide
- Drug
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- HIV/AIDS, Alcoholic Hepatitis
- Interventions
- Alcoholic Hepatitis Group, Heavy Drinking Controls without Hepatitis
- Other
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Not listed
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 20 Years to 74 Years
- Enrollment
- 2,378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2007
- U.S. locations
- 4
- States / cities
- Los Angeles, California • Iowa City, Iowa • Detroit, Michigan + 1 more
- Conditions
- Allergic Rhinitis, Allergic Conjunctivitis
- Interventions
- olopatadine, placebo
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- HIV Infections, HIV Seronegativity, Lipodystrophy
- Interventions
- Pravastatin sodium, Simvastatin, Atorvastatin calcium, Nelfinavir mesylate, Efavirenz
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 10
- States / cities
- Stanford, California • Denver, Colorado • Baltimore, Maryland + 6 more
- Conditions
- Chronic Lymphocytic Leukemia, Lymphoma, Small Lymphocytic
- Interventions
- Pacritinib, Ibrutinib
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years to 79 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Ann Arbor, Michigan • Rochester, Minnesota
- Conditions
- Cytomegalovirus Retinitis, HIV Infections
- Interventions
- Fomivirsen sodium
- Drug
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Pasadena, California • San Jose, California + 10 more
- Conditions
- Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis
- Interventions
- Abetimus sodium (LJP 394)
- Drug
- Lead sponsor
- La Jolla Pharmaceutical Company
- Industry
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 2002
- U.S. locations
- 66
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 48 more
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- filgrastim, amifostine trihydrate, cyclophosphamide, melphalan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of Kentucky
- Other
- Eligibility
- 14 Years to 70 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 4
- States / cities
- Lexington, Kentucky • Baltimore, Maryland • Philadelphia, Pennsylvania + 1 more
- Conditions
- HIV-associated Lipodystrophy Syndrome
- Interventions
- GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B, Placebo
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- T Cell Non-Hodgkin Lymphoma
- Interventions
- Senza5 CART5
- Drug
- Lead sponsor
- Vittoria Biotherapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- New York, New York • Philadelphia, Pennsylvania
- Conditions
- Asthma, Healthy
- Interventions
- CAT-354 150 mg (intravenous), CAT-354 150 mg (subcutaneous), CAT-354 300 mg (subcutaneous)
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 19 Years to 55 Years · Male only
- Enrollment
- 30 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Leukemia, Hairy Cell Leukemia, HCL
- Interventions
- Immunotoxin therapy, CAT-8015 Immunotoxin, Biological therapy
- Drug · Procedure
- Lead sponsor
- Cambridge Antibody Technology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 3
- States / cities
- Stanford, California • Chicago, Illinois • Bethesda, Maryland